
Biohaven Launches Pivotal Phase 3 Trial for Graves' Disease Therapy
Biohaven has enrolled the first patient in a pivotal Phase 3 clinical trial of BHV-1300, a novel extracellular protein degrader designed to treat Graves' disease. By targeting the underlying autoantibodies rather than suppressing thyroid function, the drug aims to provide the first new therapeutic option for the condition in seventy years.
























